• VERTIS CV: Ertugliflozin and Cardiovascular Outcomes

  2026-09-11

  The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its rigorous event-driven design also showed numerically favorable, but not statistically superior, trends for heart-failure and renal outcomes, clarifying both the evidence and limits of SGLT2 inhibitor benefit in this population.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-09-10

  The PKH26 Red Fluorescent Cell Linker Kit supplies a membrane-associated red label for cell tracing in vitro and in vivo and proliferation-oriented tracking when fluorescence is measured over time. It is intended for cell membrane lipid region fluorescent labeling, not intracellular labeling, non-membrane targets, or using fluorescence alone as a viability or cell-identity marker.

• Telmisartan in Cardiac Hypertrophy Workflows

  2026-09-10

  Use Telmisartan as a receptor-proximal control to test whether angiotensin II-driven remodeling depends on AT1R signaling. This workflow pairs hypertrophy phenotyping with RIP3/CaMKII, JAK2/STAT3, and NF-κB readouts to distinguish upstream blockade from downstream pathway modulation.

• Metoprolol: From Beta1 Blockade to Translation

  2026-09-09

  Metoprolol is more than a cardiovascular research reagent: it is a mechanistically useful probe for studying beta1-adrenergic signaling, disease-state pharmacology, and phenotype-specific responses. This article connects selective beta1-adrenoceptor antagonism with translational study design, using recent MASH pharmacokinetic evidence to show why exposure, tissue distribution, and transporter biology should be integrated into modern workflows.

• PAD4-IN-2 TFA: Tumor-Targeted NET Workflows

  2026-09-09

  PAD4-IN-2 TFA, also known as Compound 5i TFA, connects tumor targeting with mechanistic PAD4 inhibition for studies of histone H3 citrullination, NET biology, metastasis, and immune remodeling. This practical guide translates published findings into cell-based, neutrophil, imaging, and in vivo workflow decisions while highlighting controls and troubleshooting checkpoints.

• From Aβ Processing to Translational Strategy

  2026-09-08

  A mechanistic and translational framework for using (R,S)-Anatabine to connect APP processing, BACE-1 regulation, inflammation, and soluble Aβ peptide reduction across Alzheimer’s disease models.

• TG003 Cdc2-like Kinase Inhibitor Workflows

  2026-09-08

  TG003 connects kinase perturbation with measurable changes in SR-protein phosphorylation, alternative splicing, and drug-response phenotypes. This practical guide shows how to deploy it in splicing assays, exon-skipping studies, and mechanistic ovarian cancer experiments while controlling for ATP competition and CLK2 selectivity limits.

• Catalpol: From NLRP3 Biology to Assay Design

  2026-09-07

  Catalpol, also indexed as Catalpinoside, links oxidative stress, NLRP3 signaling, microglial state, and behavioral phenotypes. This article translates that evidence into a causal assay-design framework for neuroprotection research and related disease models.

• GCG, SARS-CoV-2 N Condensates, and Replication

  2026-09-07

  The reference study shows that SARS-CoV-2 nucleocapsid protein undergoes RNA-triggered liquid–liquid phase separation and identifies this condensation process as a potentially druggable step in viral replication. Its analysis of the R203K/G204R N-protein variant and the green-tea polyphenol GCG connects viral sequence variation, condensate behavior, interferon antagonism, and replication outcomes.

• Miltefosine Activates Ras/MEK/ERK in Leukopenia

  2026-09-05

  The reference study identifies Miltefosine as a potential leukopenia therapy that promotes neutrophil differentiation through Ras/MEK/ERK signaling. By combining cellular assays, an irradiation-induced mouse model, transcriptomics, network pharmacology, molecular docking, and pathway inhibition, the authors connect neutrophil recovery with restoration of hematopoietic function.

• HyperScribe™ T7 Cy3 RNA Probe Design Guide

  2026-09-04

  Explore how the HyperScribe T7 High Yield Cy3 RNA Labeling Kit can support better-designed fluorescent RNA probes for spatial and transcript-level analysis. This article connects probe chemistry with assay decisions for evaluating mRNA delivery and intracellular activity.

• Ceruletide (Caerulein) Research Guide

  2026-09-04

  Ceruletide, also called Caerulein or cerulein, is a synthetic CCK-like decapeptide used to study pancreatic secretion, gastrointestinal motility, and experimental pancreatitis. Its strongest research value is as a reproducible secretagogue and disease-model inducer, not as an established antifibrotic treatment.

• Cerulenin Reveals Leucomycin Biosynthesis

  2026-09-03

  The 1977 study by Takeshima, Kitao, and Omura showed that cerulenin selectively blocks leucomycin production in Streptomyces kitasatoensis by interfering with acetate incorporation into the macrolide aglycone. Its growing-cell, resting-cell, radiotracer, and recovery experiments provided early functional evidence that leucomycin is assembled through a fatty acid-like polyketide condensation pathway.

• Mdivi-1: Selective DRP1 Inhibitor Workflows

  2026-09-03

  Mdivi-1 provides an acute, cell-permeable way to test how DRP1-dependent mitochondrial fission influences apoptosis, stress signaling, and retinal injury. This practical guide connects mitochondrial imaging and apoptosis assay design with the emerging extracellular-matrix-to-mitochondria pathway described in Cell.

• Demethyleneberberine: NSCLC Workflow & Protocols

  2026-09-02

  Demethyleneberberine (DMB) is a versatile natural alkaloid for connecting NSCLC senescence studies with inflammatory, hepatic, intestinal, and neuroprotective models. This practical guide translates reference-study findings into formulation, dosing, assay-selection, and troubleshooting workflows.

7858 records 2/524 page Previous Next 12345 下5页 Last page